Fast Five Quiz: Relapsed and Metastatic Renal Cell Carcinoma

Elwyn C. Cabebe, MD


July 08, 2022

The treatment approach for patients with RCC is based on the histologic subtype (clear cell RCC vs non-clear cell RCC) of the tumor and prognostic risk factors, per National Comprehensive Cancer Network (NCCN) guidelines. Patients are classified into favorable-, intermediate-, and high-risk groups according to the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC); IMDC risk correlates with survival time and is the basis for the selection of treatment.

According to the NCCN, patients with lung-only metastases, good prognostic features, and good performance status may benefit from cytoreductive nephrectomy prior to the initiation of vascular endothelial growth factor (VEGF)-targeted treatments.

Chemotherapy and radiation are essentially ineffective for the treatment of all RCCs, per Makhov and colleagues.

Genetic testing is recommended in patients with a personal or family history of RCC syndromes or in patients diagnosed with RCC with characteristics associated with a potential hereditary syndrome (diagnosis at ≤ 46 years of age, bilateral tumors).

Learn more about RCC.


Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.